Thermo Fisher Scientific Inc. (NYSE:TMO) Stake Lifted by B.O.S.S. Retirement Advisors LLC

B.O.S.S. Retirement Advisors LLC increased its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 34.1% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,011 shares of the medical research company’s stock after buying an additional 1,275 shares during the quarter. B.O.S.S. Retirement Advisors LLC’s holdings in Thermo Fisher Scientific were worth $2,615,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in TMO. Silicon Valley Capital Partners bought a new position in shares of Thermo Fisher Scientific in the first quarter worth $29,000. OLD Mission Capital LLC bought a new position in shares of Thermo Fisher Scientific in the fourth quarter worth $31,000. Live Oak Investment Partners bought a new position in shares of Thermo Fisher Scientific in the fourth quarter worth $36,000. Barrett & Company Inc. bought a new position in shares of Thermo Fisher Scientific in the first quarter worth $43,000. Finally, Grey Fox Wealth Advisors LLC acquired a new stake in shares of Thermo Fisher Scientific in the fourth quarter valued at $43,000. 87.06% of the stock is currently owned by institutional investors.

Thermo Fisher Scientific Stock Down 0.0 %

TMO stock traded down $0.11 during mid-day trading on Friday, hitting $515.53. The stock had a trading volume of 5,179,741 shares, compared to its average volume of 1,216,868. The company has a current ratio of 1.42, a quick ratio of 1.02 and a debt-to-equity ratio of 0.67. Thermo Fisher Scientific Inc. has a 1-year low of $475.77 and a 1-year high of $609.85. The company has a fifty day moving average of $540.34 and a 200 day moving average of $541.69. The stock has a market capitalization of $198.97 billion, a price-to-earnings ratio of 35.24, a PEG ratio of 2.43 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, July 26th. The medical research company reported $5.15 earnings per share for the quarter, missing the consensus estimate of $5.43 by ($0.28). The firm had revenue of $10.69 billion during the quarter, compared to analyst estimates of $10.99 billion. Thermo Fisher Scientific had a return on equity of 18.59% and a net margin of 13.14%. The business’s revenue for the quarter was down 2.6% on a year-over-year basis. During the same period in the previous year, the company earned $5.51 earnings per share. On average, equities analysts expect that Thermo Fisher Scientific Inc. will post 22.37 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 13th. Stockholders of record on Friday, September 15th will be issued a dividend of $0.35 per share. This represents a $1.40 dividend on an annualized basis and a dividend yield of 0.27%. The ex-dividend date of this dividend is Thursday, September 14th. Thermo Fisher Scientific’s dividend payout ratio is 9.57%.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the company. StockNews.com upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Friday. JPMorgan Chase & Co. upped their price objective on Thermo Fisher Scientific from $660.00 to $670.00 in a report on Thursday, July 27th. Barclays upped their target price on Thermo Fisher Scientific from $590.00 to $625.00 and gave the company an “overweight” rating in a report on Thursday, July 27th. Royal Bank of Canada upped their target price on Thermo Fisher Scientific from $662.00 to $698.00 in a report on Thursday, July 27th. Finally, KeyCorp reduced their target price on Thermo Fisher Scientific from $710.00 to $640.00 in a report on Thursday, May 25th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $631.71.

Insider Activity

In related news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Thursday, August 3rd. The stock was sold at an average price of $549.00, for a total transaction of $5,490,000.00. Following the completion of the sale, the chief executive officer now owns 141,330 shares in the company, valued at approximately $77,590,170. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 3rd. The stock was sold at an average price of $549.00, for a total value of $5,490,000.00. Following the completion of the sale, the chief executive officer now owns 141,330 shares in the company, valued at approximately $77,590,170. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Gianluca Pettiti sold 3,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 30th. The stock was sold at an average price of $557.77, for a total value of $1,673,310.00. Following the completion of the sale, the executive vice president now owns 17,556 shares of the company’s stock, valued at approximately $9,792,210.12. The disclosure for this sale can be found here. In the last quarter, insiders have sold 28,700 shares of company stock valued at $15,799,270. Insiders own 0.32% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the United States and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, clinical next-generation sequencing, bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.